Characteristics of patients treated with CD28-costimulated CART19
| Characteristic . | Total 59 (100%) . | Flu/Cy 37 (62.7%) . | Benda 22 (37.3%) . | P value . |
|---|---|---|---|---|
| Age at infusion, y | ||||
| ≤65 | 49 (83.1%) | 30 (81.1%) | 19 (86.4%) | .601 |
| >65 | 10 (16.9%) | 7 (18.9%) | 3 (13.6%) | |
| Diagnosis | ||||
| LBCL | 48 (81.4%) | 33 (89.2%) | 15 (68.2%) | .045 |
| FL | 11 (18.6%) | 4 (11.8%) | 7 (31.8%) | |
| Sex | ||||
| Female | 17 (28.8%) | 10 (27.0%) | 7 (31.8%) | .694 |
| Male | 42 (71.2%) | 27 (73.0%) | 15 (68.2%) | |
| Previous therapies, n | ||||
| Median (IQR) | 2 (2-4) | 2 (2-3) | 2 (1-4) | .585 |
| Previous ASCT | ||||
| No | 48 (81.4%) | 26 (70.3%) | 22 (100%) | .005 |
| Yes | 11 (18.6%) | 11 (29.7%) | 0 (0%) | |
| Bridging therapy | ||||
| No | 12 (20.3%) | 10 (27.0%) | 2 (9.1%) | .098 |
| Yes | 47 (79.7%) | 27 (73.0%) | 20 (90.9%) | |
| Bulky disease (n = 54) | ||||
| No | 45 (83.3%) | 30 (88.2%) | 15 (75%) | .208 |
| Yes | 9 (16.7%) | 4 (11.8%) | 5 (25%) | |
| ECOG grade (n = 55) | ||||
| ≤1 | 54 (98.2%) | 35 (100%) | 19 (95.0%) | .182 |
| >1 | 1 (1.8%) | 0 (0%) | 1 (5.0%) | |
| LDH levels before LD (n = 57) | ||||
| Normal | 30 (52.6%) | 16 (45.7%) | 14 (63.6%) | .187 |
| Elevated | 27 (47.4%) | 19 (54.3%) | 8 (36.4%) | |
| Platelet count | ||||
| ≥50 × 109/L | 57 (96.6%) | 35 (96.6%) | 22 (100%) | .267 |
| <50 × 109/L | 2 (3.4%) | 2 (5.4%) | 0 (0.0%) |
| Characteristic . | Total 59 (100%) . | Flu/Cy 37 (62.7%) . | Benda 22 (37.3%) . | P value . |
|---|---|---|---|---|
| Age at infusion, y | ||||
| ≤65 | 49 (83.1%) | 30 (81.1%) | 19 (86.4%) | .601 |
| >65 | 10 (16.9%) | 7 (18.9%) | 3 (13.6%) | |
| Diagnosis | ||||
| LBCL | 48 (81.4%) | 33 (89.2%) | 15 (68.2%) | .045 |
| FL | 11 (18.6%) | 4 (11.8%) | 7 (31.8%) | |
| Sex | ||||
| Female | 17 (28.8%) | 10 (27.0%) | 7 (31.8%) | .694 |
| Male | 42 (71.2%) | 27 (73.0%) | 15 (68.2%) | |
| Previous therapies, n | ||||
| Median (IQR) | 2 (2-4) | 2 (2-3) | 2 (1-4) | .585 |
| Previous ASCT | ||||
| No | 48 (81.4%) | 26 (70.3%) | 22 (100%) | .005 |
| Yes | 11 (18.6%) | 11 (29.7%) | 0 (0%) | |
| Bridging therapy | ||||
| No | 12 (20.3%) | 10 (27.0%) | 2 (9.1%) | .098 |
| Yes | 47 (79.7%) | 27 (73.0%) | 20 (90.9%) | |
| Bulky disease (n = 54) | ||||
| No | 45 (83.3%) | 30 (88.2%) | 15 (75%) | .208 |
| Yes | 9 (16.7%) | 4 (11.8%) | 5 (25%) | |
| ECOG grade (n = 55) | ||||
| ≤1 | 54 (98.2%) | 35 (100%) | 19 (95.0%) | .182 |
| >1 | 1 (1.8%) | 0 (0%) | 1 (5.0%) | |
| LDH levels before LD (n = 57) | ||||
| Normal | 30 (52.6%) | 16 (45.7%) | 14 (63.6%) | .187 |
| Elevated | 27 (47.4%) | 19 (54.3%) | 8 (36.4%) | |
| Platelet count | ||||
| ≥50 × 109/L | 57 (96.6%) | 35 (96.6%) | 22 (100%) | .267 |
| <50 × 109/L | 2 (3.4%) | 2 (5.4%) | 0 (0.0%) |
ASCT, autologous stem cell transplantation; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.